One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Galmed Pharmaceuticals Ltd. logo
Galmed Pharmaceuticals Ltd. GLMD
$ 4.63 21.05%
report update icon

Quarterly report 2026-Q2
added 11-16-2026

Galmed Pharmaceuticals Ltd. Financial Statements 2025-2011 | GLMD

Annual Financial Statements Galmed Pharmaceuticals Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

3.19 M 1.25 M 96.9 K 112 K 2.36 M 84.5 M 102 M 149 M 63.9 M 46.1 M 69.4 M 67.3 M - - -

Shares

4.31 M 931 K 231 K 140 K 1.64 M 21.3 M 21.1 M 18.1 M 12.5 M 11.4 M 11.1 M 10.3 M - - -

Historical Prices

0.74 1.34 0.42 0.8 1.44 3.97 4.85 8.24 5.12 5.2 4.61 9.49 - - -

Net Income

-10.3 M -7.52 M -6.91 M -17.9 M -32.5 M -28.8 M -20.5 M -9.86 M -12.3 M -17 M 10.6 M 9.1 M -17.5 M -3.15 M -

Revenue

- - - - - - - 2.04 M 1.08 M 467 K - - - - -

Operating Income

- - - - - -30.2 M -22.4 M -10.7 M -12.4 M - - - - - -

Interest Expense

741 K 516 K 580 K -215 K -414 K 1.44 M -1.92 M 934 K 65 K 35 K - - - - -

EBITDA

- 83 K 31 K 35 K 42 K -30.2 M -22.3 M -10.3 M -12.1 M -16.7 M 10.7 M 9.11 M -14.6 M -3.13 M -

Operating Expenses

8.51 M 6.28 M 7.49 M 17.7 M 32.9 M 30.2 M 22.4 M 12.8 M 13.4 M 17.3 M 10.9 M 9.14 M - - -

General and Administrative Expenses

3.64 M 3.3 M 3.92 M 4.66 M 5.66 M 4.13 M 4.2 M 4.44 M 3.8 M 3.08 M 3.25 M 2.48 M 7.36 M 694 K -

All numbers in USD currency

Quarterly Income Statement Galmed Pharmaceuticals Ltd.

2026-Q2 2025-Q4 2025-Q3 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

952 K 4.31 M 5.46 M 494 K 931 K 6.29 M 231 K 1.68 M - - - - 25.1 M - 25.1 M - 21.3 M - 21.2 M - 21.1 M - 21.1 M - 21 M - 15.7 M - 14.4 M - 12.2 M - 12.1 M - 11.1 M - 11.1 M - 11.1 M - 11.1 M - - - 9.74 K - - - - - - - - - - -

Net Income

-2.72 M -10.3 M -1.89 M -2.5 M -7.52 M -1.12 M -6.91 M -1.59 M - - - - - - -8.4 M -8.9 M - - -5.53 M -6.06 M - - -4.17 M -3.49 M - - -2.68 M -2.51 M - - -2.69 M - - - -4.31 M - - - -2.35 M - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - 270 K - - - 270 K - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - - - - - - - - -5.82 M - - - -4.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 741 K 203 K 103 K 516 K 103 K 580 K 278 K - - - - - - - - - - 290 K - - - 532 K - - - 90 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - 83 K 83 K 83 K 83 K 31 K 17 K - - - - - - - - - - -5.82 M - - - -4.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

2.78 M 8.51 M 2.1 M 2.11 M 6.28 M 1.22 M 7.49 M 1.87 M - - - - - - 8.41 M - - - 5.82 M - - - 4.7 M - - - 2.78 M - - - 2.7 M - - - 4.22 M - - - 2.53 M - - - - - - - - - - - - - - - - -

General and Administrative Expenses

993 K 3.64 M 1.01 M 1.05 M 3.3 M 688 K 3.92 M 1.06 M - - - - - - 1.38 M - - - 845 K - - - 1.21 M - - - 1.1 M - - - 624 K - - - 861 K - - - 967 K - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Galmed Pharmaceuticals Ltd. GLMD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Galmed Pharmaceuticals Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.62 4.18 % $ 561 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 59.5 -3.02 % $ 121 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.1 -1.79 % $ 2.71 B israelIsrael
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA